Modulation of orbitofrontal-striatal reward activity by dopaminergic functional polymorphisms contributes to a predisposition to alcohol misuse in early adolescence.


Journal

Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142

Informations de publication

Date de publication:
04 2019
Historique:
pubmed: 19 6 2018
medline: 15 5 2020
entrez: 19 6 2018
Statut: ppublish

Résumé

Abnormalities in reward circuit function are considered a core feature of addiction. Yet, it is still largely unknown whether these abnormalities stem from chronic drug use, a genetic predisposition, or both. In the present study, we investigated this issue using a large sample of adolescent children by applying structural equation modeling to examine the effects of several dopaminergic polymorphisms of the D1 and D2 receptor type on the reward function of the ventral striatum (VS) and orbital frontal cortex (OFC), and whether this relationship predicted the propensity to engage in early alcohol misuse behaviors at 14 years of age and again at 16 years of age. The results demonstrated a regional specificity with which the functional polymorphism rs686 of the D1 dopamine receptor (DRD1) gene and Taq1A of the ANKK1 gene influenced medial and lateral OFC activation during reward anticipation, respectively. Importantly, our path model revealed a significant indirect relationship between the rs686 of the DRD1 gene and early onset of alcohol misuse through a medial OFC × VS interaction. These findings highlight the role of D1 and D2 in adjusting reward-related activations within the mesocorticolimbic circuitry, as well as in the susceptibility to early onset of alcohol misuse.

Sections du résumé

BACKGROUND
Abnormalities in reward circuit function are considered a core feature of addiction. Yet, it is still largely unknown whether these abnormalities stem from chronic drug use, a genetic predisposition, or both.
METHODS
In the present study, we investigated this issue using a large sample of adolescent children by applying structural equation modeling to examine the effects of several dopaminergic polymorphisms of the D1 and D2 receptor type on the reward function of the ventral striatum (VS) and orbital frontal cortex (OFC), and whether this relationship predicted the propensity to engage in early alcohol misuse behaviors at 14 years of age and again at 16 years of age.
RESULTS
The results demonstrated a regional specificity with which the functional polymorphism rs686 of the D1 dopamine receptor (DRD1) gene and Taq1A of the ANKK1 gene influenced medial and lateral OFC activation during reward anticipation, respectively. Importantly, our path model revealed a significant indirect relationship between the rs686 of the DRD1 gene and early onset of alcohol misuse through a medial OFC × VS interaction.
CONCLUSIONS
These findings highlight the role of D1 and D2 in adjusting reward-related activations within the mesocorticolimbic circuitry, as well as in the susceptibility to early onset of alcohol misuse.

Identifiants

pubmed: 29909784
pii: S0033291718001459
doi: 10.1017/S0033291718001459
doi:

Substances chimiques

DRD1 protein, human 0
Receptors, Dopamine D1 0
Receptors, Dopamine D2 0
ANKK1 protein, human EC 2.7.11.1
Protein Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

801-810

Subventions

Organisme : Medical Research Council
ID : G0901858
Pays : United Kingdom
Organisme : Medical Research Council
ID : 93 558
Pays : United Kingdom
Organisme : CIHR
Pays : Canada

Auteurs

Travis E Baker (TE)

Department of Psychiatry,Universite de Montreal, CHU Ste Justine Hospital,Montreal,Canada.

Natalie Castellanos-Ryan (N)

Department of Psychiatry,Universite de Montreal, CHU Ste Justine Hospital,Montreal,Canada.

Gunter Schumann (G)

Institute of Psychiatry, King's College London,London,UK.

Anna Cattrell (A)

Institute of Psychiatry, King's College London,London,UK.

Herta Flor (H)

Department of Cognitive and Clinical Neuroscience,Central Institute of Mental Health,Medical Faculty Mannheim,Heidelberg University,Square J5, Mannheim,Germany.

Frauke Nees (F)

Department of Cognitive and Clinical Neuroscience,Central Institute of Mental Health,Medical Faculty Mannheim,Heidelberg University,Square J5, Mannheim,Germany.

Tobias Banaschewski (T)

Department of Child and Adolescent Psychiatry,Central Institute of Mental Health,Faculty of Clinical Medicine Mannheim,Medical Faculty Mannheim,Heidelberg University,Square J5, 68159 Mannheim,Germany.

Arun Bokde (A)

Discipline of Psychiatry,School of Medicine and Trinity College Institute of Neurosciences, Trinity College,Dublin,Ireland.

Rob Whelan (R)

Discipline of Psychiatry,School of Medicine and Trinity College Institute of Neurosciences, Trinity College,Dublin,Ireland.

Christian Buechel (C)

University Medical Centre Hamburg-Eppendorf,Haus S10, Martinistr. 52, Hamburg,Germany.

Uli Bromberg (U)

University Medical Centre Hamburg-Eppendorf,Haus S10, Martinistr. 52, Hamburg,Germany.

Dimitri Papadopoulos Orfanos (D)

Neurospin, Commissariat à l'Energie Atomique, CEA-Saclay Center,Paris,France.

Juergen Gallinat (J)

Department of Psychiatry and Psychotherapy,Campus Charité Mitte, Charité,Universitätsmedizin Berlin,Charitéplatz 1, Berlin,Germany.

Hugh Garavan (H)

Departments of Psychiatry and Psychology,University of Vermont,05405 Burlington, Vermont,USA.

Andreas Heinz (A)

Department of Psychiatry and Psychotherapy,Campus Charité Mitte, Charité,Universitätsmedizin Berlin,Charitéplatz 1, Berlin,Germany.

Henrik Walter (H)

Department of Psychiatry and Psychotherapy,Campus Charité Mitte, Charité,Universitätsmedizin Berlin,Charitéplatz 1, Berlin,Germany.

Rüdiger Brühl (R)

Physikalisch-Technische Bundesanstalt,Abbestr. 2 - 12, Berlin,Germany.

Penny Gowland (P)

School of Psychology, University of Nottingham, University Park,Nottingham,UK.

Tomáš Paus (T)

Rotman Research Institute, University of Toronto,Toronto,Canada.

Luise Poustka (L)

Department of Child and Adolescent Psychiatry,Central Institute of Mental Health,Faculty of Clinical Medicine Mannheim,Medical Faculty Mannheim,Heidelberg University,Square J5, 68159 Mannheim,Germany.

Jean-Luc Martinot (JL)

Rotman Research Institute, University of Toronto,Toronto,Canada.

Herve Lemaitre (H)

Institut National de la Sante et de la Recherche Medicale, INSERM CEAUnit1000, Imaging & Psychiatry, University Paris Sud,91400 Orsay,France.

Eric Artiges (E)

Department of Psychiatry,Universite de Montreal, CHU Ste Justine Hospital,Montreal,Canada.

Marie-Laure Paillère Martinot (ML)

Department of Psychiatry,Universite de Montreal, CHU Ste Justine Hospital,Montreal,Canada.

Michael N Smolka (MN)

Department of Psychiatry and Neuroimaging Center,Technische Universität Dresden,Dresden,Germany.

Patricia Conrod (P)

Department of Psychiatry,Universite de Montreal, CHU Ste Justine Hospital,Montreal,Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH